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PropranololAbstract Infantile hemangiomas are the most common benign childhood tumors, they are more
common in girls and premature babies, and all races are affected with a slight preponderance in
whites (Metry). These lesions most commonly occur on the head and neck area, but they can occur
anywhere on the body (Paller, 2011). Here, we describe a case of bilateral facial mandibular segment
hemangioma with deep and superﬁcial components involving both parotid glands which was man-
aged successfully with propranolol.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Case report
Here we present the case of a full term baby boy born at
37 weeks of gestation by an elective cesarean section after an
uneventful pregnancy. One to two weeks after birth, the par-
ents noticed small telangiectasias and strawberry colored ma-
cules on the skin overlying both parotid areas, lower lip, tip
of the tongue and the anterior aspect of the chin and neck.
The lesions started a growth phase at the age of 3–4 weeks,
and the patient was seen in our clinic at the age of three and
a half months, at that time he had extensive bilateral parotid
hemangiomas with both superﬁcial and deep components,and had superﬁcial hemangiomas on the lower lip, chin, preau-
ricular area, neck and anterior chest (Figs. 1 and 2). The lesion
on the lower lip was partially ulcerated and was associated
with bleeding upon feeding. The patient was noticed to have
a stridor which was related to the extensive size of the heman-
gioma partially obstructing the airway.
The infant was admitted to the pediatric ward for full inves-
tigation and evaluation for internal organ involvement aswell as
other associated congenital anomalies such as PHACES syn-
drome. (Posterior fossamalformations,Hemangiomas,Arterial
anomalies, Cardiac anomalies and aortic coarctation, Eye
abnormalities and Sternal clefting and supraumbilical raphe)
(Paller, 2011). The evaluation for systemic involvement and
radiological studieswas carried out by the pediatric cardiologist.
No evidence of associated congenital anomalies or internal
organ hemangiomas were found upon appropriate radiological
studies of the head (Fig. 3), neck, chest, and abdomen. An
echocardiography was also done, with no signs of cardiac
anomalies.
Figure 1 Bilateral cervicofacial hemangiomas with lower lip,
neck area and anterior chest area involvement demonstrating both
a deep and a superﬁcial component, at the time of ﬁrst
presentation.
Figure 2 A right side view of the hemangioma at the time of ﬁrst
presentation.
Figure 3 CT scan of the head showing the depth of the
hemangioma and the bilateral parotid gland involvement.
Figure 4 Gradual improvement seen at 1 month following
treatment.
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(Hemoglobin of 8.4 gm/dl), iron level was 13 lg/dl (low), and
this was dealt with iron supplementation. Liver, renal and
thyroid function tests were within normal. Cultures taken from
ulcerated areas were negative for any bacterial growth.The decision to intervene was made due to the extensive size
of the hemangioma, difﬁculty of feeding due to recurrent bleed-
ing from the ulcerated areas on the lower lip, and the stridor the
patient was noticed to have. A potential complication that was
considered and emphasized the need for intervention was the
risk of delayed language development due to partial obstruction
of the auditory canals which was noticed upon examination.
After full evaluation by the pediatric cardiologist, the infant
was started on propranolol 0.78 mg/kg/day in EDD (equally di-
vided doses), with gradual increasing of the dose as tolerated,
while monitoring vital signs and blood glucose levels periodi-
cally. The ﬁnal dose reached was 1.8 mg/kg/day given in
EDD, on which the patient was discharged, and followed up
in the outpatient clinic on a monthly basis, both in the pediatric
cardiology clinic and the dermatology clinic. The hemangioma
showed a signiﬁcant improvement in size and color after 2 weeks
from starting therapy and continued to shrink in size with each
follow up visit (Figs. 4–6). Finally, at the age of 12 months pro-
pranolol was stopped after gradual tapering started in the last
month of treatment under the recommendation and supervision
of the pediatric cardiologist, the decision to taper treatment was
based on the assumption that the active growth phase of the
hemangioma usually ends by the ﬁrst year. The patient had no
regrowth on 6 months, 12 months, and 18 months of follow
up after the discontinuation of treatment, but a ﬁbrofatty resi-
due remained in the lower lip area and the anterior chest area.
2. Discussion
Infantile hemangiomas are the most common soft tissue tu-
mors occurring during infancy. They are noticed more in baby
girls and in premature babies, and they are more common in
whites (Metry and Hebert, 2000). Other risk factors may in-
clude advanced maternal age, multiple pregnancies, and preg-
nancies complicated with placenta previa and pre-eclampsia
(Metry and Hebert, 2000; Paller, 2011).
Infantile hemangiomas may be superﬁcial, deep or may be
composed of both a superﬁcial and a deep component as in
our case.
Figure 6 Signiﬁcant improvement seen at 4 months after
treatment.
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three phases, a growth phase known as the proliferative phase
which usually lasts up to the age of 12 months and occasion-
ally longer. A plateau phase as the growth seizes which usually
occurs at 12–18 months of age, and a third phase of spontane-
ous involution which occurs between the ages of 3 and 10 years
in most cases (Metry and Hebert, 2000; Paller, 2011).
Hemangiomas with a deep component particularly ones
involving the parotid glands as our case usually take a longer
time to involute and some may not undergo complete involu-
tion (Metry and Hebert, 2000). Some superﬁcial hemangiomas
located on the lips as our patient had, may also fail to involute
completely (Metry and Hebert, 2000) and may be associated
with recurrent bleeding due to ulceration and therefore lead
to difﬁculty of feeding as was experienced by our patient.
The decision to intervene is based on several factors includ-
ing the size and location of the infantile hemangioma, as
hemangiomas located in critical areas such as the eyes or the
preauricular areas may lead to a compromise or loss of vision
and delayed language development due to conductive hearing
loss respectively (Greene et al., 2004). In general, infantile
hemangiomas that interfere with function or lead to destruc-
tion of vital structures or obstruct airways or cause signiﬁcant
disﬁgurement or are associated with life threatening complica-
tions such as congestive heart failure need intervention
(Greene et al., 2004; Menezes, 2011). Our patient had massive
bilateral cervicofacial hemangiomas involving the parotid
glands which were partially obstructing both auditory canals
with the possible risk of delayed language development. Along
with the stridor due to partial airway obstruction caused by the
hemangioma involving the anterior neck area, and in addition
to the difﬁculty of feeding that the infant experienced, as well
as the disﬁgurement and parental anxiety that it caused, we
decided that intervention was necessary.
Management options for infantile hemangiomas that do
not interfere with vital functions or cause any disﬁgurement
or complications are mainly active nonintervention (Vibhu
and Masarat, 2010). But those that require intervention, man-
agement options include, medical therapy, LASER therapyFigure 5 Further improvement seen at 2 months after treatment.usually PDL (pulse dye LASER) and Nd:YAG LASER (Neo-
dymium–Yttrium aluminum garnet), cryotherapy, compressive
therapy, and surgical resection (Sinno et al., 2010; Vibhu and
Masarat, 2010). Medical therapy includes topical, intralesional
or systemic corticosteroids, topical imiquimod, Interferon al-
pha 2a or alpha 2b, vincristine, cyclophosphamide, and intrale-
sional bleomycin (Paller, 2011; Bagazgoitia et al., 2011; Greene
et al., 2004; Vibhu and Masarat, 2010). Recently, successful
treatment with captopril was also documented by S.T Tan
et al. (Tan et al., 2012). All of these treatments have very well
known side effects (Metry and Hebert, 2000). Systemic gluco-
corticosteroids are reported to cause fussiness, irritability, gas-
tric irritation, hypertension and HPA suppression (George
et al., 2004). Decreased rate of growth and weight gain have
also been documented (Vibhu and Masarat, 2010). Intralesion-
al steroids may cause skin atrophy, depigmentation, necrosis,
and if used for periorbital hemangiomas may cause embolism
to the retinal artery (Vibhu and Masarat, 2010). Interferon al-
pha 2a or 2b use is usually reserved for life threatening heman-
giomas and can be associated with spastic diplegia in 20% of
patients (Paller, 2011), more commonly encountered side ef-
fects with interferon alpha include fever, irritability, and mal-
aise. Neutropenia, anemia and elevated liver transaminases
have also been reported (Paller, 2011). Side effects related to
captopril use included hypotension with subsequent renal
impairment, skin rashes and gastrointestinal upset (Tan
et al., 2012). Cryotherapy may be associated with scarring
and surgery is also risky as it may lead to scarring, facial asym-
metry and temporary or permanent facial nerve paralysis,
along with other complaints and possibly even death (Sinno
et al., 2010).
Less commonly used modalities of treatment include Beca-
plermin (recombinant platelet derived growth factor) which is
mainly used for ulcerated infantile hemangiomas especially in
the diaper area (Vibhu and Masarat, 2010).
In 2008 Le´aute´-Labre`ze et al. reported the use of propran-
olol a non selective beta blocker in the management of infantile
hemangiomas that require intervention (Le´aute´-Labre`ze et al.,
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been suggested by Le´aute´-Labre`ze et al., 2008. We used a dose
of 1.8 mg/kg/day in EDD in our patient as suggested by the
pediatric cardiologist. The speculated mechanism by which
propranolol works is through vasoconstriction, blocking of
the proangiogenic signals such as vascular endothelial growth
factor (VEGF), basic ﬁbroblast growth factor (bFGF), and
matrix metalloproteinases 2 and 9 (MMP), and on the long
term, propranolol may induce apoptosis in the proliferating
endothelial cells. (Morais et al., 2011; Sans et al., 2009). Pro-
pranolol therapy requires careful monitoring of the infant
for bradycardia, hypotension, hypoglycemia and hypothermia
(Morais et al., 2011; Bonifazi et al., 2008; Bagazgoitia et al.,
2011; Menezes, 2011; Sans et al., 2009). Other side effects of
propranolol include bronchospasm especially in patients with
reactive airway disease, skin rashes, fatigue, sleep disturbance
and gastrointestinal discomfort (Morais et al., 2011; Sans
et al., 2009) and hyperkalemia was reported in one case as a
potential life threatening complication (Pavlakovic et al.,
2010). Therefore, we opted to admit the patient for the ﬁrst
2 weeks of therapy for evaluation and monitoring purposes,
and our patient seemed to have tolerated the treatment very
well without any adverse events.3. Conclusion
Our patient responded wonderfully and promptly to propran-
olol therapy, and has tolerated the therapy with no serious side
effects. Parental anxiety was reduced and prolonged disﬁgure-
ment was avoided. No regrowth was experienced on 6 months,
12 months, and 18 months of follow up after discontinuation
of propranolol.
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